RIP kinase Inhibitor

RIP2 kinase inhibitor 2 is a receptor interacting protein-2 (RIP2) kinase inhibitor extracted from patent WO/2014043437 A1, compound example 9.

RIP2 Kinase Inhibitor 3 is a highly potent and selective inhibitor of receptor interacting protein-2 (RIP2) Kinase with an IC₅₀ of 1 nM .

Necrostatin-34 (Nec-34), a RIPK1 kinase inhibitor, stabilizes RIPK1 kinase in an inactive conformation by occupying a distinct binding pocket in the kinase domain.

(Rac)-GSK547 is the racemate of GSK547. GSK547 is a highly selective and potent inhibitor of receptor-interacting serine/threonine protein kinase 1 (RIP1), inhibits macrophage-mediated adaptive immune tolerance in pancreatic cancer.

RI-962 is a potent and selective receptor-interacting protein kinase 1 (RIPK1) inhibitor. RI-962 inhibits RIPK1 with an IC₅₀ value of 35.0 nM. RI-962 can be used for the research of nervous system diseases and inflammatory diseases.

WEHI-345 analog is the analog of WEHI-345. WEHI-345 is a potent and selective RIPK2 kinase inhibitor with an IC₅₀ of 0.13 μM, which delays RIPK2 ubiquitylation and NF-κB activation on oligomerization domain (NOD) stimulation.

RIPK3 Human Pre-designed siRNA Set A contains three designed siRNAs for RIPK3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

Kongensin A is a natural product isolated from Croton kongensis. Kongensin A is an effective, covalent HSP90 inhibitor that blocks RIP3-dependent necroptosishas. Kongensin A is a potent necroptosis inhibitor and an apoptosis inducer. Kongensin A has potential anti-necroptosis and anti-inflammation applications.

OD36hydrochloride is a RIPK2 inhibitor with an IC₅₀ of 5.3 nM. OD36 hydrochloride is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. OD36 hydrochloride shows ALK2-directed activity with K_Ds of 37 nM.

Ripk3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Ripk3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

HTH-01-091 TFA is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor, with an IC₅₀ of 10.5 nM. HTH-01-091 TFA also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK and CLK2. HTH-01-091 TFA can be uesd for breast cancer research.

AV123 (compound 12) is a non-cytotoxic RIPK1 inhibitor (IC₅₀=12.12 µM). AV123 blocks the TNF-α-induced necroptotic (EC₅₀=1.7 μM) but not the apoptotic cell death. AV123 can be used in the study of necrotic chronic conditions such as ischemia-reperfusion injury of the brain, heart and kidney, inflammatory diseases, neurodegenerative diseases and infectious diseases.

Necrostatin-1 (Standard) is the analytical standard of Necrostatin-1. This product is intended for research and analytical applications. Necrostatin-1 (Nec-1) is a potent and cross the blood-brain barrier necroptosis inhibitor with an EC50 of 490 nM in Jurkat cells. Necrostatin-1 inhibits RIP1 kinase (EC50=182 nM). Necrostatin-1 is also an IDO inhibitor.

RIP2 kinase inhibitor 1 (compound 11) is a potent and selective receptor interacting protein 2 (RIP2) kinase inhibitor with an IC₅₀ of 0.03 μM for RIP2 FP. RIP2 kinase inhibitor 1 is used for autoinflammatory disorders.

RIPK1-IN-3 (Example 38), a RIPK1 inhibitor, extracted from patent WO2018148626A1, possesses anti-inflammatory proprieties.

RIPK1-IN-10 is a potent RIPK1 inhibitor, example 37, extracted from patent WO2021160109.

Primidone-d₅ is the deuterium labeled Primidone. Primidone is the orally active inhibitor for TRPM3 (IC₅₀ = 0.6 μM), RIP kinase and voltage-gated sodium channel, and the antagonist for GABA receptor. Primidone can be used as the analgesic and anticonvulsant agent.

RIPK3-IN-7 is a RIPK3 inhibitor that suppresses the RIPK3-mediated necroptosis pathway. RIPK3-IN-7 can be used for research on necroptosis and inflammation-related diseases.

RIP1-IN-1 is an orally active RIP1 inhibitor with strong RIP1 binding affinity (K_d: 110 nM). RIP1-IN-1 exhibits strong anti-necroptosis activity. RIP1-IN-1 effectively inhibits the formation of necrosomes by blocking the phosphorylation of RIP1, RIP3 and MLKL signaling pathways. RIP1-IN-1 inhibits necroptosis and can be used in the study of acute liver injury.

RIPK1-IN-30 (compound 24) is a potent RIPK1 inhibitor with an IC₅₀ of 2.01 μM. RIPK1-IN-30 exhibits protective effects in HT-29 cell model of TSZ-induced necroptosis with an EC₅₀ of 6.77 μM.